Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 vs Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT06394492Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tizetatug rezetecan in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Suzhou Suncadia Biopharmaceutical. Started May 2024; status: recruiting.
02
Drugs
tizetatug rezetecan
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06394492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394492.